Vision / Company History
"Composing the Future"
for all customers
Company History & Transitions
Period Focused on Contract Manufacturing
Prior to 1985, approximately 50% of our business was in contract manufacturing and we were a relatively small company with an annual turnover of 300 million yen. Quality management was our top priority and we were not yet involved in new product development.
Taiyo Sekken Co., Ltd. was established in Hirai, Edogawa-ku, Tokyo.
Company name was changed to KOKYU ALCOHOL KOGYO CO., LTD.
Operation of new esterification plant started.
Growing Demand for Esters and Plant Relocation
Aiming at breaking away from contract manufacturing and developing our own products, we manufactured higher alcohol flakes during this period. This period saw the easing of regulations for cosmetic ingredients and technologies and production methods for the formulation of esters and expanding our production capacity became a key priority compelling us to relocate our plant to Taiei-machi (currently Narita-shi).
Manufacturing of high-purity higher alcohols started.
Tokyo office was opened in Kanda, Chiyoda-ku, Tokyo.
Head office and plant were moved to Narita, Chiba.
Inauguration of Narita Plant and Expansion in South Korea
With the new esterification plant in Narita, our production capacity increased by approximately five times. During this period, our core product, "ISOSTEARIC ACIDS" were launched.
We also developed a full-fledged approach to South Korea, a country to which we had exported only small amounts at that time. Marketing strategies based on high-quality products at competitive prices compared to our competitors enabled us to increase sales. During this period, we also started investigating raw material sources from overseas.
Tokyo office was moved to Nihonbashi Honcho, Chuo-ku, Tokyo.
Automatic warehouse was newly built.
The first expansion of hydrogenation plant was completed.
New Product Development and Global Expansion
From 2000, our experience in penetrating the Korean market led the way to selling our products in Europe and the USA. Our goal was and still is to substitute ingredients from animal or petroleum origins to plant-based materials and develop functional ingredients. "HAILUCENT ISDA" and "RISOCAST DA" were launched. In 2007, the European Union enforced a new chemical regulation, "REACH", compelling us to establish an affiliate company, ESTENITY, in Lyon, France, in 2008.
Premises for the expansion in Taiei Kogyo Danchi were purchased.
The second expansion of esterification plant was completed.
ISO14001 certification was obtained.
Reinforcement work of the esterification plant was completed.
Tokyo office was moved to Nihonbashi Ningyocho, Chuo-ku, Tokyo.
Automated warehouse of hazardous materials was newly built.
ESTENITY was established as the affiliated company in Lyon, France.
Product Differentiation by Quantifying Functionality
In 2010, we started the process of quantifying the feel of our products on the skin. Sensory evaluations of lipsticks and lip glosses were now mostly converted into numerical values, making possible suggestions based on objective data.
ESTENITY laboratory was established in Lyon, France.
Reinforcement work of the hydrogenation plant was completed.
Capitalization was increased to 17 million yen.
Ester production capacity was increased.
Fractionating facility was expanded.
Premises were purchased to build a new plant and a research building in Taiei Kogyo Danchi.
Esterification plant (reactor and fractionating facilities) was renovated.
Certificated as “Business Innovation Planning Company” from Chiba prefecture.
Started to build The Second Plant and R&D Center in Taiei Kogyo Danchi.
New Plant and R&D Center Established and the New Challenge of Entering the Pharmaceutical Market
Since 2011, we had been focusing on new product development based on skin science and also technical application to haircare formulations.
Following a long preparatory period, construction of the Second Plant and R&D Center was completed in 2016. We embarked on a new chapter to enter fully into the pharmaceutical market.
The Second Plant & R&D Center was completed.